Table 1 COVID-19 clinical trials with ruxolitinib and interferon alpha.
From: COVID-19 and myeloproliferative neoplasms: some considerations
| National Clinical Trial Number (NCT) | Sponsor/collaborator | Study design | Regimen dose duration | Patients | Primary endpoints | Phase | Status | |
|---|---|---|---|---|---|---|---|---|
| Ruxolitinib | NCT04414098 | Novartis Pharmaceuticals (Clinica Zabala, Argentina) | OL | 5-mg BID for 14 days | Hospitalized, laboratory-confirmed, ARDS | % of patients with clinical worsening (defined by a requirement of FIO2 > 50% and/or mechanical respiratory assistance), time frame 14 days | Phase 2 | Not yet recruiting |
| NCT04331665 | University Health Network, Toronto, Canada | SA/OL | 10-mg BID for 14 days, followed by 5-mg BID for 2 days, and 5-mg QD for 1 day | Hospitalized, laboratory-confirmed, pneumonia | % of patients with clinical worsening (defined by a requirement of FIO2 > 60% and/or mechanical respiratory assistance), time frame 6 months | N/A | Not yet recruiting | |
| NCT04348071 | University of Colorado, Denver, CO, USA | SA/OL | 10-mg BID for 14 days | Hospitalized, laboratory-confirmed, pneumonia | Clinical status as assessed on eight-point scale at day 15 | Phase 2, Phase 3 | Not yet recruiting | |
| NCT04377620 | Incyte Corporation (Multi-center) | R/DB | 5 and 15-mg BID for 28 days | Hospitalized, laboratory-confirmed, ARDS | 28-day mortality rate | Phase 3 | Recruiting | |
| NCT04477993 | University of Sao Paulo General Hospital, Sao Paulo, Brazil | R/DB | 5-mg BID for 14 days | Hospitalized, laboratory-confirmed, ARDS | A composite outcome of death or ICU admission or mechanical ventilation at day 14 | Phase 2, Phase 3 | Recruiting | |
| NCT04362137 | Novartis Pharmaceuticals/ Incyte Corporation (Multi-center) | R/DB | 5-mg BID for 14 days, can be extended up to 28 days | Hospitalized, laboratory-confirmed, ARDS | A composite outcome of death or ICU admission or mechanical ventilation, time frame 29 days | Phase 3 | Recruiting | |
| NCT04359290 | Philipps University Marburg Medical Center, Marburg, Germany | SA/OL | 10-mg BID at day 1, dose escalation up to 15-mg BID at day 2-28 | Hospitalized, laboratory-confirmed, ARDS | Overall survival, time frame 28 days | Phase 2 | Recruiting | |
| NCT04334044 | Grupo Cooperativo de Hemopatías Malignas, Hospital Angeles Lomas, Huixquilucan, Mexico | SA/OL | 5-mg BID for 14 days | Laboratory-confirmed, ARDS | Recovery of pneumonia, time frame 14 days | Phase 1, Phase 2 | Recruiting | |
| NCT04338958 | University of Jena, Jena, Germany | NR/SA/OL | 10-mg BID, dose escalation up to 20-mg BID for 7 days | Hospitalized, laboratory-confirmed, severe pneumonia | Overall response as assessed on 25% reduction in baseline hyperinflammation score (CIS), time frame 7 days | Phase 2 | Recruiting | |
| NCT04403243 | Lomonosov Moscow State University Medical Research and Educational Center, Moscow, Russia | R/OL | 5-mg BID for 10 days | Laboratory-confirmed, pneumonia | Change from baseline as assessed on clinical assessment score (CAS) at day 12 | Phase 2 | Recruiting | |
| IFNalpha | NCT04320238 | Shanghai Jiao Tong University School of Medicine, Shanghai, China | NR/OL | Interferon α1β nasal drops, 2–3 drops for each nostril per time, QID | Formally serving medical staff, not directly in contact with COVID-19 patients | Number of new cases, time frame 6 weeks | Phase 3 | Recruiting |
| NCT04293887 | Tongji Hospital, Wuhan, Hubei, China | R/OL | Interferon α1β 10 µg per nebulizer BID | Laboratory-confirmed, pneumonia, symptoms onset <7 days | Incidence of side effects as assessed on development of dyspnea, SPO2 ≤ 94%, respiratory rate ≥24 breaths/min, time frame 14 days | Phase 1 | Not yet recruiting |
